# 📊 RAG vs. Graph RAG Performance Evaluation Report

**Evaluated Model**: `gemma3:1b`  
**Timestamp**: 2026-07-02 23:06:57

## 📈 Performance Summary

| Query | RAG Mode | Retrieval Time | Gen Time | Total Time | Words | Sources | Relations |
|---|---|:---:|:---:|:---:|:---:|:---:|:---:|
| Q1: Does metformin improve survival in HER2-posit... | **Standard** | 0.037s | 9.95s | 9.99s | 249 | 3 | N/A |
| | **Graph RAG** | 0.017s | 6.83s | 6.85s | 467 | 3 | 10 |
|---|---|---|---|---|---|---|---|
| Q2: Does metformin combine synergistically with o... | **Standard** | 0.023s | 3.13s | 3.15s | 219 | 3 | N/A |
| | **Graph RAG** | 0.016s | 5.29s | 5.30s | 433 | 3 | 0 |
|---|---|---|---|---|---|---|---|
| Q3: Does metformin reduce chemotherapy-induced to... | **Standard** | 0.051s | 4.25s | 4.30s | 303 | 3 | N/A |
| | **Graph RAG** | 0.016s | 5.60s | 5.62s | 394 | 3 | 0 |
|---|---|---|---|---|---|---|---|

## 🔎 Detailed Responses & Comparison

### Q1: Does metformin improve survival in HER2-positive breast cancer?

#### Standard RAG Response
> Okay, here's a structured and concise summary of the available scientific evidence regarding metformin in treating HER2-positive breast cancer based on provided sources:
> 
> **Overall Summary:** Evidence suggest that **metformin might offer a potential protective effect against HER2-driven breast cancers**, specifically for her2-positve patients. However, more research is needed to understand how this happens.
> 
> **Evidence Analysis:**
> 
> *   **Source Paper 1 (Metformin Mechanism - Systematic Review/Meta-Analysis):** The mechanism proposed here focuses on metformin as having anticancer effects through modulation of glucose metabolism and potentially impacting breast cancer development by reducing risk factors. While the evidence is still limited, it suggests a role for metformin in enhancing antitumor properties.
> 
> *   **Source Paper 2 (methabolin and chemotherapy - Randomized Controlled Trial):** The clinical trial demonstrating metformin’s benefits with neoadjuvant chemotherapy has revealed that metformin modestly enhanced pcr rates, particularly in the HER2-positive subgroup. Notably, it showed a statistically significant difference between the treated and control groups but the effect was not substantial enough to be clinically important..
> 
> *   **Source Paper 3 (wbp2 and metabolic gene):**  The clinical trial found that wBP2’s effects include disrupting metformin response by reversing the amp:atp ratio in breast cancer cells, reducing neuropathy, suggesting a mechanism involving metabolic pathways.
> 
> 
> **Conclusion:** The evidence does *not* definitively support metformin as a primary treatment for HER2-positive breast cancer. However, it suggests potential benefit where modified metabolic regulation can be beneficial to improve outcomes specifically for this cohort of patients through targeted strategies exploring wBP2’s role and understanding its relation to metformin efficacy.

#### Graph RAG Response
> Okay, Here's an analysis responding to your requests, structured and concise:
> 
> **Overall Assessment:** The provided connection reveals a nuanced perspective surrounding metformin's potential benefits in breast cancer patients, indicating complexities regarding subgroups. Many of the claims presented are partial agreements recognizing potential value despite discrepancies across various patient groups.
> 
> 
> **Detailed Analysis by Claim & Relationship Points:**
> 
> 1.  **Claim A (BMI/Metformin Benefit):** The stance is **Neutral**, supported primarily by the study's interaction investigation between variables that suggest adverse effects or possibly reduced benefit, implying a nuanced evaluation and not demonstrating definitive change for everyone.
> 
> 
> 2.  **Claim B (WBP2 & Metformin Inhibition):**  The stance is **Contradict**. Based on earlier clinical trials suggesting metformin’s effectiveness against HER2-positive breast cancers, this study explicitly demonstrates that WBP2 attenuates its effect in the context of these cells. The evidence supports the hypothesis that metformin *does* interfere with this pathway, indicating a biological mechanism.
> 
> 
> 3.  **Relationship (Partially Agreement):** There is a **PARTIAL_AGREEMENTS | Analyst Confidence: 0.8 | Avg Evidence Weight: 5.75** - This analysis highlights how claim A’s focus on BMI/metformin benefits are being presented with WBP2's interference highlighting the contrasting pathways and mechanisms of action between them. 
> 
> 4.  **Relationship (Partially Agreement):** There is a **PARTIAL_AGREEMENTS | Analyst Confidence: 0.8 | Avg Evidence Weight: 5.75** - This analysis also highlights how claim A focuses on HER2-positive patients, while claim B does not corroborate this benefit in subgroups other than the study sample.
> 
> 
> 
> 5.  **Claim A (Metformin Response & Chemoimmunotherapy):** The stance is **Support**, with stronger evidence supporting a potentially positive effect on chemotherapy response in the HER2-positive subset, showing that metformin enhances it compared to neoadjuvant chemoterapy. A key point of this benefit is reduced peripheral neuropathy, further suggesting usefulness; and support points towards an expanded scope of clinical use with metformin.
> 
> 
> 6.  **Claim B (Metformin & Non-Significant Outcome):** The stance is **Neutral**. The result shows a non-significant difference between metformin and controls regarding overall pcr rates in comparison which provides no definitive conclusion on the benefits for HER2 positive breast cancer.
> 
> 
> 7. **Claim C (Potential for Metformin in HER2 Patients)**: The response confirms a potential benefit to metformin for patients with HER2-positive disease based on correlations and evidence, therefore strengthening it’s ability as a possible treatment option.
> 
> 
> 
> 8.  **Relationship (Partially Agreement):** There's an **PARTIAL_AGREEMENTS | Analyst Confidence: 0.8 | Avg Evidence Weight: 6.75** - This analysis illustrates the benefit found through increasing levels of metformin in HER2-positive patient groups, while also finding that there isn’t a positive impact on pathological complete response rates when added to neoadjuvant chemotherapy and as a result, supports the statement of metformin being beneficial to some patients and not others.
> 
> 
> **Note:**  This interpretation is based solely on providing textual justifications given from source material. It does not constitute deep clinical review – more analysis would likely be required.

#### Analysis
- **Relations Traversed**: Found 10 claim relations linked to the query's retrieved papers.
- **Quality Improvement**: Graph RAG successfully connected contradicting and agreeing studies directly, allowing the model to discuss clinical consensus and conflicts explicitly.

---

### Q2: Does metformin combine synergistically with other drugs for triple-negative breast cancer?

#### Standard RAG Response
> Here's the response summarizing the provided scientific evidence regarding the synergistic effect of metformin with other treatments for triple-negative breast cancer (TNBC):
> 
> **The evidence suggests that metformin shows potential synergy with other treatments for TNB, though further research is needed to precisely determine this.**
> 
> *   [Source Paper 1] supports a mechanism where metformin reduces breast cancer incidence.  However it doesn't discuss synergistic treatment effects.
> *   [Source Paper 2]:  The open-label phase 2 randomized controlled trial of metformin in TNBC provides preliminary evidence for its potential reusability in this context, suggesting that metformin could benefit as an adjunct therapy in combination with chemotherapy or surgery. However, the study remains ongoing and the results are not yet conclusive, providing a relatively weak link between metformin use.
> *   [Source Paper 3]  Highlights systematic reviews of randomized clinical trials that have investigated metformin's efficacy as a treatment for breast cancer.  It points out the current limited understanding of the benefits of metformin compared to other studies focused specifically on breast cancer – highlighting both potential benefit and the absence of comprehensive evidence related to TNB, and even the lack of specific research regarding synergistic effects.
> 
> **Overall, there’s an open approach toward exploring this synergistic effect but the evidence is nascent.**  Additional studies are needed using more standardized methodologies to confirm these findings definitively.
> 
> 
> 

#### Graph RAG Response
> Okay, here's a concise assessment of whether metformin synergistically combined with other drugs can mitigate triple-negative breast cancer (TNBC) according to the provided data, directly responding to your question and providing critical context based on the research:
> 
> **Conclusion:** Based on the evidence provided, the data suggests a potentially synergistic effect between metformin and other treatments for TNPBC. Specifically:
> 
> **Evidence Supporting Synergy:**  Two sources point toward this synergy:
> 
> *   **[Source Paper 2]**: This study highlights that metformin is used as an anti-diabetic drug and research focused on repurposing it to treat tnbc which indicates potential for synergism in treating TNBC. [Graph Connection Y – describes a clinical trial where the study design includes a phase 2 randomized controlled trial of the intervention arm, and the primary purpose is treatment]. This suggests that metformin can potentially enhance the effects of other therapies in TNPBC by regulating glucose levels or modulating metabolic pathways present in the disease.
> 
> *   **[Source Paper 3]**: Systematic Review demonstrates that metformin has significant research interest among breast cancer patients with a potential benefit in treatment via rcts involving the use of metformin and compared to existing approaches. In their systematic review, [Graph Connection Y – details the scope of the scoping review, which covered all rcts examining metformin's use for breast cancer patients]  It identified that while the evidence is scattered, many did not fully consider individual patient phenotypes and this lack highlighted significant gaps in understanding. Specifically when considering individual patient features—such as those specific genetic marker patterns – combined interventions like metformin, along with chemotherapy or other targeted drugs may offer better outcomes.
> 
> **Contradictions & Lack of Robustness:** The data presents *potential* synergy but lacks definitive evidence. [Source Paper 3] focuses more on the general literature and leaves the specifics of synergistic clinical improvements ambiguous. Furthermore, there are no explicitly presented measurements that determine if metformin is synergistically increasing survival rates or addressing aspects of TNBC specifically; all supporting evidence suggests it may be helpful in mitigating various effects associated with diabetes type2. There also isn't a study examining how synergistic combinations affect patient outcome in terms of recurrence-free survival or disease-free survival after standard treatment.  This makes definitive conclusions more difficult without additional analyses.
> 
> 
> **Overall Assessment:** The available evidence warrants cautious optimism but requires further investigation into specific phenotypes. Combining metformin with established TNBC therapies might offer a more supportive environment for patient outcomes – especially if the genetic profiles of cancer patients are utilized.
> 
> 
> 
> Do you need me to refine this response or provide more detailed analyses, such as summarizing potential mechanisms or identifying gaps in knowledge?

#### Analysis
- **Relations Traversed**: 0 relationships linked to retrieved papers found in `contradictions.json`.
- **Quality Improvement**: Equivalent to standard RAG due to absence of graph connections for this subset.

---

### Q3: Does metformin reduce chemotherapy-induced toxicities?

#### Standard RAG Response
> Metformin may reduce chemotherapy-related toxicities. Here’s a detailed response based solely on the provided context:
> 
> **Evidence:**
> 
> *   [Source Paper 1] –  The study stated that “this study aimed to evaluate the impact of metformin on survival and adverse events among cancer patients receiving radiotherapy and concurrent metformin." - **Provides evidence for a possible benefit**.  The pooled overall survival rate was found to be non-significant across multiple subgroups (ors: 1.00-1.77).
> 
> *   [Source Paper 2] – The paper suggests that “metformin, the most commonly prescribed medication for type 2 diabetes, is associated with a lower risk of developing several cancers” - **Focuses on metformin as a potential mitigating factor**. This contributes to understanding why research is being conducted.
> 
> *   [Source Paper 3] – "Metformin: A dual-role player in cancer treatment and prevention: a comprehensive systematic review and meta-analysis." The review stated that “metformin intake seemed linked to a lower risk of cancers” - **Further supports the potential anti-cancer effects**. Also emphasizes inconsistency with previous results, but the evidence points towards a potentially protective effect.
> 
> **Lack/Conflicting Evidence:**
> 
> *   [Source Paper 2] -  There is conflicting survival trends noted for prostate, oesophageal, and non-small cell lung cancer across diabetic conditions
> *   Further research is needed on cancer types and diabetic conditions in [Source Paper 1]. The evidence includes a "gap" on the specific types of cancers.
> 
> **Summary:**
> 
> Meta-analyses conducted in the provided sources indicate that metformin may have a small impact on survival rates, potentially reducing heart failure risk in breast cancer patients, but doesn’t show any significant impact across overall survival based solely on the presented research data. Despite inconsistencies in observing tumor progression and mortality, [source paper 3] suggests that metformin intake seems to lower cancers. Therefore, further investigations are needed into specific cancer types to determine more precise impacts of metformin treatment and benefit.

#### Graph RAG Response
> Here’s a response addressing your question, drawing from the provided data:
> 
> **Does metformin reduce chemotherapy-induced toxicities? – Initial Examination of Evidence**
> 
> The available evidence suggests that metformin may have a modest effect on improving outcomes in cancer patients receiving radiotherapy alongside cisplatin chemotherapy, but the evidence is not conclusive regarding reductions in chemotherapy-related toxicity. Here’s a breakdown of the information based on the provided resources:
> 
> 
> **1. Survival and Adverse Events:**
> 
> * **Overall Survival Rates (OR & 95% CI)** studies found no statistically significant difference between metformin users and nonusers across various cancer subgroups.  In particular, the rates were inconsistent for diabetic subgroups such as prostate, oesophageal, and non-small cell lung cancers, and breast cancer. The risk of heart failure was significantly lower with metformin in patients with breast Cancer.
> * **Specific Adverse Event Findings:** Reports indicate a possible decrease in heart complications, particularly in breast cancer patients.
> 
> **2. Mechanisms & Effects (Based on Source Paper 2):**
> 
> * **Mechanism of Action for Reduced Toxicity – Overview**: The source paper identifies the mechanism of metformin involving inhibition of tumor growth and enhanced radiosensitivity, possibly contributing to reduced toxicity.
> * **Cancer-Specific Findings:** Analyses showed that in breast cancer patients, metformin users had a significantly lower risk to heart failure (OR: 0.72; 95% CI: 0.64–0.81),  and in colorectal cancers, this risk of events remained at 0.62 (OR : 0.62; 95% CI: 0.51 – 0.76).
> 
> **3. Meta-analysis Findings – Conflicts & Agreement:**
> 
> * **Limited Evidence Regarding Cancer Type -  Lack Consistency**: Most analyses (65 out of total 75 studies) showed inconsistent results across cancer types and the impact on patient mortality.
> * **Metformin Use is Linked to Lower Risks :** The overall meta-analysis revealed a significant reduction in cancer risk (RR 0.72; 95% CI: 0.64-0.81), with moderate risks in breast, colorectal cancers.
> 
> **4.  Gaps & Conclusion:**
> 
> 
> 
> The data presents mixed results and identifies several gaps such as the lack of consistency across cancer types. Notably, the review finds the observational-based designs to hinder confirming the causality relationships between metformin use and outcomes. 
> 
> Essentially, while some findings suggest potential benefit, further research focused on larger, well-conducted trials (such as large prospective studies) is urgently required to understand whether metformin truly reduces chemotherapy-induced toxicities definitively, considering this data's contradictions within cancer types and experimental designs.
> 
> 
> Let me know if you’d like a deeper dive into any particular aspect of this information!

#### Analysis
- **Relations Traversed**: 0 relationships linked to retrieved papers found in `contradictions.json`.
- **Quality Improvement**: Equivalent to standard RAG due to absence of graph connections for this subset.

---
